Understanding Leber hereditary optic neuropathy (LHON)
Reading, identifying faces and distinguishing colors may become difficult while some side vision remains useful. The onset can be simultaneous or separated between eyes; age at onset and degree of visual impairment vary. It is inaccurate to describe everyone as completely blind. [1] [2]
Most established LHON is linked to mitochondrial DNA variants, often one of three common variants. Some people carrying a pathogenic variant never develop visual loss. A nuclear gene, DNAJC30, also causes a recessive LHON form; inheritance advice must therefore follow the actual genetic result rather than a universal maternal-inheritance rule. [2] [6]
One condition. Different experiences.
Explore different selected symptom features, then read how they may vary. These examples are not stages or a clinical test.
Original VisualSim schematic illustrations, informed by the cited clinical descriptions. These are not study figures, patient recordings or validated severity levels.
A central area loses useful detail
Letters or facial detail can become indistinct in the area being looked at directly. The effect may be a gap, reduced clarity or poor contrast rather than a sharply outlined black spot. [1]
Colors become harder to separate
Color discrimination can decline with acuity. A person may still detect an object but have difficulty identifying its color or reading its label. [1] [2]
The two eyes can change at different times
One eye may decline before the other. This can alter the experience of reading and depth-dependent tasks during an evolving episode; a simulator cannot predict the interval or eventual function. [1] [2]
From genetic mechanism to useful support
Original educational pathway; neither a pedigree nor a predicted course. [1] [2] [6]
Original VisualSim teaching diagram · © VisualSim. Clinical basis in linked sources; not a published study figure. Image provenance.- Genetic result
Identify the mitochondrial or nuclear cause.
- Optic nerve function
Measure each eye’s acuity, color and field.
- Individual plan
Discuss evidence, family counseling and rehabilitation.
What is happening—and what remains uncertain
Retinal ganglion cells send visual information through their axons in the optic nerve. LHON-related mitochondrial dysfunction particularly affects this pathway and central vision. The visible optic disc may initially appear relatively normal, so a normal-looking eye surface or early examination does not resolve the diagnosis. [1] [2]
The common mitochondrial forms involve respiratory-chain complex I. The 2021 DNAJC30 study identified a different, nuclear-encoded pathway involving complex I repair. These related energy mechanisms do not mean every genetic subtype has the same inheritance, recovery pattern or response to a proposed treatment. [6]
What can look similar?
LHON and dominant optic atrophy
Both can affect central detail and color, but dominant optic atrophy more often has an insidious childhood presentation and different genetic inheritance. The pattern and genetic testing matter more than matching an example image. [2] [8]
LHON and optic neuritis
Optic neuritis is an inflammatory optic neuropathy and often includes pain with eye movement. LHON is usually painless, but absence or presence of pain alone cannot establish either diagnosis. [1]
Mitochondrial and recessive LHON
Most familiar LHON pedigrees reflect mitochondrial inheritance. DNAJC30-related recessive disease is a documented exception, making genetics-led family counseling essential. [6]
Similar-looking symptoms can have different causes. A matching picture cannot establish a diagnosis.
What an assessment may involve
- Document visual function in each eyeAcuity, color testing and visual fields help describe central impairment. Optic nerve examination and OCT add structural information; none of these alone identifies the causal variant. [1] [2]
- Use a genetics strategy matched to the caseTesting commonly begins with frequent mitochondrial variants and can expand when suspicion remains. A negative limited panel is different from excluding every genetic optic neuropathy; ask what was tested and whether nuclear causes are relevant. [1] [6]
- Check competing and additional causesHistory, examination and selected imaging or laboratory tests help distinguish acquired optic neuropathies. Report neurological or cardiac symptoms because some genetic presentations extend beyond vision. [1] [2]
What may help—and what is still being studied
Discuss jurisdiction-specific treatment options
The European Medicines Agency authorizes idebenone for visual impairment from LHON in adults and adolescents aged 12 or older under an experienced clinician. This is not a worldwide approval, a guarantee of recovery or a reason to start supplements without specialist review. [3]
Interpret the evidence in full
RHODOS did not meet its primary endpoint, although secondary and subgroup findings supported possible benefit. LEROS subsequently reported favorable outcomes using an external natural-history comparison; this strengthens discussion but does not remove nonrandomized-study limitations. [4] [5]
Combine risk counseling and rehabilitation
Clinicians may address tobacco, heavy alcohol use, nutritional health and medicines alongside genetic counseling. Rehabilitation should respond to current task difficulty rather than wait for a final level of vision or a future disease-modifying therapy. [1] [7]
What this can mean for daily life
Make reading flexible
Try magnification, adjustable spacing and text-to-speech with a low-vision professional. The best combination depends on remaining central function and the task, not just an acuity number. [7]
Use accessible identification
Audio labels, high-contrast organization and accessible phone settings can reduce reliance on small print and color alone. Test tools in the lighting where they will be used. [7]
Plan school and work access early
Request accessible electronic materials and assistive-technology assessment. Explain specific tasks that are difficult rather than assuming the diagnosis tells teachers or employers what support is needed. [7]
Connect without substituting peer advice for care
A patient community can help families share practical experiences and reduce isolation. Treatment claims, supplements and genetic interpretations discussed by peers still need the treating team’s assessment. [1]
Bring a clearer description to your appointment
Choose the questions you want to discuss. These choices stay in this page’s memory.
Research, with the context left in
Selected studies and guidance, with their populations and limitations. These are curated educational summaries, not a complete systematic review or a formal evidence rating.
A randomized placebo-controlled trial of idebenone in LHON (RHODOS)
The primary endpoint was not statistically significant. Secondary and subgroup analyses suggested potential benefit, supporting further investigation rather than uniform recovery expectations. [4]
Limits and applicability: Short follow-up, a rare heterogeneous disease and subgroup analyses limit certainty. Findings do not establish the same effect for every variant or onset interval.
LEROS nonrandomized controlled trial
Reported favorable visual outcomes for selected disease phases and genetic subgroups in a larger treatment program. [5]
Limits and applicability: External controls can differ in ascertainment, natural recovery and follow-up; matching cannot eliminate confounding. It is not a concurrent randomized comparison.
Impaired complex I repair causes recessive LHON
Established a recessive nuclear-gene cause of the LHON phenotype and linked it to complex I repair biology. [6]
Limits and applicability: Selected families and laboratory models do not establish population prevalence or provide randomized proof of treatment response.
Questions researchers still need to answer
- Which patients and genetic subtypes obtain a meaningful lasting treatment benefit, beyond spontaneous recovery?
- How can trials measure reading, independence and quality of life as well as letter-chart outcomes?
Trusted places to go next
Selected clinical references, research, practical support and ways to connect. Official pages checked 24 October 2026; each entry explains its scope and region.
LHON Society
Patient-led information, community membership and research updates. Membership asks for personal information on the charity’s own site; peer support does not replace clinical advice.
Connections listed by the organization.
United Mitochondrial Disease Foundation
Mitochondrial disease education, support ambassadors, specialist discovery and research participation information. This lay organization does not provide medical advice.
Connections listed by the organization.
NANOS specialist directory
Search neuro-ophthalmology professionals. Listing does not guarantee an appointment, insurance coverage or emergency access.
National Eye Institute low-vision resources
Information on vision rehabilitation, accessible devices and task adaptations; ask locally about referral and service availability.
Questions you may still have
Does carrying a variant mean I will definitely lose vision?
No. Reduced penetrance is well recognized. A genetics professional can explain what is known for the particular variant without promising an individual outcome. [2] [6]
Is LHON always inherited from the mother?
Common mitochondrial forms follow maternal inheritance. DNAJC30-related LHON is autosomal recessive, so the genetic result must guide counseling. [6]
Sources, image credits and review status
Compiled by VisualSim from clinical references and published research. Sources checked 24 October 2026. Independent clinical review has not been recorded; no named clinical reviewer or clinical validation is claimed. Research evidence and its limitations are linked below.
- NANOS — Leber Hereditary Optic Neuropathy (n.d.; institution).
Public source checked for the stated scope; source checking is not clinical review.
Checked 2026-10-24 · Public page checked - MedlinePlus Genetics — Leber hereditary optic neuropathy (n.d.; institution).
Public source checked for the stated scope; source checking is not clinical review.
Checked 2026-10-24 · Public page checked - European Medicines Agency — Raxone assessment and authorization (n.d.; institution).
Public source checked for the stated scope; source checking is not clinical review.
Checked 2026-10-24 · Public page checked - Klopstock et al. — A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy (2011; trial).
Original indexed abstract and methods checked; direct PMC reader challenged. Primary endpoint and subgroup limitations retained.
Checked 2026-10-24 · Abstract/indexed material checked; complete full-text review not claimed - Yu-Wai-Man et al. — Therapeutic benefit of idebenone in patients with LHON: The LEROS nonrandomized controlled trial (2024; trial).
Public source checked for the stated scope; source checking is not clinical review.
Checked 2026-10-24 · Full text checked - Stenton et al. — Impaired complex I repair causes recessive Leber’s hereditary optic neuropathy (2021; observational).
Original genetic/functional article verified; the related JCI147734 page is commentary, not the primary study.
Checked 2026-10-24 · Full text checked - National Eye Institute — Low Vision (2025; institution).
Public source checked for the stated scope; source checking is not clinical review.
Checked 2026-10-24 · Public page checked - Stanford Neuro-ophthalmology Illustrated — Hereditary optic neuropathies (2019; institution).
Archive based on a 2012 textbook; phenotype used, fixed progression and blanket no-treatment statements not adopted.
Checked 2026-10-24 · Public page checked
The simulator helps people communicate an experience. It cannot diagnose a condition, measure a visual field, or establish that someone is safe to drive.